|
Aug 1
|
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
|
|
Aug 1
|
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
|
|
Jul 31
|
Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
|
|
Jul 31
|
Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON
|
|
Jul 30
|
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
|
|
Jul 30
|
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
|
|
Jul 21
|
Why Alkermes Tumbled On Its Positive Narcolepsy Study
|
|
Jul 21
|
Takeda Pharmaceutical Receives FDA 510(k) Clearance for Hyqvia Devices
|
|
Jul 21
|
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
|
|
Jul 2
|
What's Fueling Tempus AI's Explosive Sales Growth?
|
|
Jul 1
|
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
|
|
Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
|
Jun 4
|
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
|
|
May 27
|
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent
|
|
May 27
|
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
|
|
May 20
|
Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform
|
|
Mar 14
|
TAK or DSNKY: Which Is the Better Value Stock Right Now?
|
|
Mar 13
|
Takeda’s $770M deal deepens Big Pharma’s omics push
|